The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

Martin J. van den Bent*, Pim J. French, Daniel Brat, Joerg C. Tonn, Mehdi Touat, Benjamin M. Ellingson, Robert J. Young, Johan Pallud, Andreas von Deimling, Felix Sahm, Dominique Figarella Branger, Raymond Y. Huang, Michael Weller, Ingo K. Mellinghoff, Tim F. Cloughsey, Jason T. Huse, Kenneth Aldape, Guido Reifenberger, Gilbert Youssef, Philipp KarschniaHoutan Noushmehr, Katherine B. Peters, Francois Ducray, Matthias Preusser, Patrick Y. Wen

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

8 Citations (Scopus)
5 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science